100 related articles for article (PubMed ID: 8168126)
1. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about.
Sawyers CL; Denny CT
Cell; 1994 Apr; 77(2):171-3. PubMed ID: 8168126
[No Abstract] [Full Text] [Related]
2. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.
Golub TR; Barker GF; Lovett M; Gilliland DG
Cell; 1994 Apr; 77(2):307-16. PubMed ID: 8168137
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms.
Golub TR; Barker GF; Stegmaier K; Gilliland DG
Curr Top Microbiol Immunol; 1996; 211():279-88. PubMed ID: 8585959
[No Abstract] [Full Text] [Related]
4. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.
Carroll M; Tomasson MH; Barker GF; Golub TR; Gilliland DG
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14845-50. PubMed ID: 8962143
[TBL] [Abstract][Full Text] [Related]
5. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein.
Jousset C; Carron C; Boureux A; Quang CT; Oury C; Dusanter-Fourt I; Charon M; Levin J; Bernard O; Ghysdael J
EMBO J; 1997 Jan; 16(1):69-82. PubMed ID: 9009269
[TBL] [Abstract][Full Text] [Related]
6. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581.
Tomasson MH; Sternberg DW; Williams IR; Carroll M; Cain D; Aster JC; Ilaria RL; Van Etten RA; Gilliland DG
J Clin Invest; 2000 Feb; 105(4):423-32. PubMed ID: 10683371
[TBL] [Abstract][Full Text] [Related]
7. Signaling in leukemia: which messenger to kill?
Pear WS
J Clin Invest; 2000 Feb; 105(4):419-22. PubMed ID: 10683370
[No Abstract] [Full Text] [Related]
8. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2).
Ross TS; Bernard OA; Berger R; Gilliland DG
Blood; 1998 Jun; 91(12):4419-26. PubMed ID: 9616134
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein.
Besançon F; Atfi A; Gespach C; Cayre YE; Bourgeade MF
Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8081-6. PubMed ID: 9653143
[TBL] [Abstract][Full Text] [Related]
10. Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta).
Bourgeade MF; Défachelles AS; Cayre YE
Blood; 1998 May; 91(9):3333-9. PubMed ID: 9558390
[TBL] [Abstract][Full Text] [Related]
11. [TIF1γ: a tumor suppressor gene in chronic myelomonocytic leukemia].
Aucagne R; Droin N; Solary E; Bastie JN; Delva L
Med Sci (Paris); 2011; 27(8-9):696-8. PubMed ID: 21880252
[No Abstract] [Full Text] [Related]
12. Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors.
Geissler K; Jäger E; Barna A; Alendar T; Ljubuncic E; Sliwa T; Valent P
Leukemia; 2016 Nov; 30(11):2280-2281. PubMed ID: 27585952
[No Abstract] [Full Text] [Related]
13. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia.
Padron E; Yoder S; Kunigal S; Mesa T; Teer JK; Al Ali N; Sekeres MA; Painter JS; Zhang L; Lancet J; Maciejewski JP; Epling-Burnette PK; Sotomayor E; Komrokji RS; List AF
Blood; 2014 Jun; 123(23):3675-7. PubMed ID: 24904105
[No Abstract] [Full Text] [Related]
14. [The role of TEL and AML1 genes in the pathogenesis of hematologic malignancies].
Zuna J
Cas Lek Cesk; 2001 Mar; 140(5):131-7. PubMed ID: 11347199
[TBL] [Abstract][Full Text] [Related]
15. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
16. Role of p21ras in hormone signalling and cell growth/transformation.
Blackmore PF
Adv Exp Med Biol; 1992; 321():143-6. PubMed ID: 1333165
[No Abstract] [Full Text] [Related]
17. [Comparison of the mode of action of ras p 21 with those of protein kinase A and C in the gene expression].
Hori Y; Kaibuchi K; Takai Y
Tanpakushitsu Kakusan Koso; 1991 May; 36(7):1032-6. PubMed ID: 1651531
[No Abstract] [Full Text] [Related]
18. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia.
Tono C; Xu G; Toki T; Takahashi Y; Sasaki S; Terui K; Ito E
Leukemia; 2005 Oct; 19(10):1843-4. PubMed ID: 16079889
[No Abstract] [Full Text] [Related]
19. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia.
Buijs A; Bruin M
Leukemia; 2007 May; 21(5):1104-8. PubMed ID: 17301809
[No Abstract] [Full Text] [Related]
20. Protein tyrosine kinases and cancer.
Kolibaba KS; Druker BJ
Biochim Biophys Acta; 1997 Dec; 1333(3):F217-48. PubMed ID: 9426205
[No Abstract] [Full Text] [Related]
[Next] [New Search]
